The University of British Columbia

British Columbia Cancer Agency Branch

Cava Healthcare Inc.

Neurodyn, Inc.

David Williams

Raymond John Andersen

Wilfred A Jefferies

Reinhard Gabathuler

Marianne Dorothy Sadar

Nasrin R Mawji

Jun Wang

Mike Leblanc

Lilian Nohara

Jaswinder Bains

Gerald Krystal

Christopher J Ong

Lu Yang

Christopher Ariel Shaw

Alice Mui

Lu-Ping Yan

Christohper A Shaw

Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Curcuphenol compounds for increasing MHC-I expression

This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided. 

Diglycidic ether derivative therapeutics and methods for their use

Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Small molecule inhibitors of N-terminus activation of the androgen receptor

The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.

Ship 1 modulators

This invention provides compound having a structure of Formula I or Formula II  Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).

Sterol glucoside toxins

The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitosterol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).

Growing community of inventors

Vancouver, Canada

David Williams